COLL
insider transactionsCOLLEGIUM PHARMACEUTICAL, INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-87.5K
0 buy · 87.5K sell
Net value · 365d
-$3.4M
$0 in · $3.4M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
8
0 buy · 87.5K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Director
$0
8.7K sh
Own New
-
Exercise·M
Director
$143.5K
8.7K sh · $16.49
Own +8%
-
Grant·A
Director
$0
15.5K sh
Own +515%
-
Sell·S
Director
$681
20 sh · $34.05
Own -0%
-
Exercise·M
Director
$0
8.7K sh
Own New
-
Sell·S
Director
$142.5K
4.1K sh · $34.54
Own -5%
-
Exercise·M
Director
$143.5K
8.7K sh · $16.49
Own +11%
-
Grant·A
Director
$0
17.5K sh
Own New
-
Grant·A
Director
$0
8.7K sh
Own +45%
-
Grant·A
Director
$0
8.7K sh
Own +49%
-
Grant·A
Director
$0
8.7K sh
Own +12%
-
Grant·A
Director
$0
8.7K sh
Own +9%
-
Grant·A
Director
$0
8.7K sh
Own +17%
-
Grant·A
Director
$0
8.7K sh
Own +14%
-
Sell·S
Director
$161.9K
4.5K sh · $35.97
Own -20%
-
Exercise·M
Director
$0
8.7K sh
Own New
-
Sell·S
Director
$323.5K
8.7K sh · $37.18
Own -12%
-
Exercise·M
Director
$143.5K
8.7K sh · $16.49
Own +14%
-
Sell·S
EVP & General Counsel · 10b5-1
$488.1K
14.0K sh · $34.92
Own -15%
-
Other·F
EVP & General Counsel
$315.8K
8.8K sh · $35.72
Own -11%
-
Sell·S
EVP & General Counsel · 10b5-1
$228.1K
6.2K sh · $36.65
Own -6%
-
Sell·S
EVP & Chief Commercial Officer · 10b5-1
$145.9K
3.6K sh · $40.99
Own -5%
-
Sell·S
EVP & Chief Commercial Officer · 10b5-1
$1.9M
46.4K sh · $40.36
Own -38%
-
Other·F
EVP & General Counsel
$130.0K
2.8K sh · $46.75
Own -3%
-
Grant·A
EVP & General Counsel
$0
9.0K sh
Own +10%
-
Grant·A
EVP & General Counsel
$0
22.2K sh
Own +32%
-
Other·F
Colleen Tupper KEY
EVP & Chief Financial Officer
$1.2M
26.7K sh · $46.75
Own -15%
-
Other·F
Colleen Tupper KEY
EVP & Chief Financial Officer
$554.5K
11.9K sh · $46.75
Own -6%
-
Grant·A
Colleen Tupper KEY
EVP & Chief Financial Officer
$0
32.7K sh
Own +21%
-
Grant·A
Colleen Tupper KEY
EVP & Chief Financial Officer
$0
26.4K sh
Own +21%
-
Other·F
EVP and Chief Medical Officer
$539.4K
11.5K sh · $46.75
Own -11%
-
Other·F
EVP and Chief Medical Officer
$275.7K
5.9K sh · $46.75
Own -5%
-
Grant·A
EVP and Chief Medical Officer
$0
22.8K sh
Own +27%
-
Grant·A
EVP and Chief Medical Officer
$0
14.3K sh
Own +20%
-
Other·F
EVP & Chief Commercial Officer
$1.0M
21.6K sh · $46.75
Own -15%
-
Other·F
EVP & Chief Commercial Officer
$466.4K
10.0K sh · $46.75
Own -7%
-
Grant·A
EVP & Chief Commercial Officer
$0
30.7K sh
Own +25%
-
Grant·A
EVP & Chief Commercial Officer
$0
19.0K sh
Own +18%
-
Other·F
Vikram Karnani KEY
President and CEO
$528.1K
11.3K sh · $46.75
Own -5%
-
Grant·A
Vikram Karnani KEY
President and CEO
$0
32.5K sh
Own +18%
-
Grant·A
Vikram Karnani KEY
President and CEO
$0
79.3K sh
Own +81%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 8, 2026 | Gino Santini | Exercise M | 8.7K | $0 |
| Jun 8, 2026 | Gino Santini | Exercise M | 8.7K | $143.5K |
| May 21, 2026 | Garen G Bohlin | Grant A | 15.5K | $0 |
| May 18, 2026 | John Gordon Freund | Sell S | 20 | $681 |
| May 15, 2026 | John Gordon Freund | Exercise M | 8.7K | $0 |
| May 15, 2026 | John Gordon Freund | Sell S | 4.1K | $142.5K |
| May 15, 2026 | John Gordon Freund | Exercise M | 8.7K | $143.5K |
| May 14, 2026 | Donovan Michael Glancy | Grant A | 17.5K | $0 |
| May 14, 2026 | Carlos V Paya | Grant A | 8.7K | $0 |
| May 14, 2026 | Nancy Lurker | Grant A | 8.7K | $0 |
| May 14, 2026 | John Gordon Freund | Grant A | 8.7K | $0 |
| May 14, 2026 | Gino Santini | Grant A | 8.7K | $0 |
| May 14, 2026 | Rita J. Balice-Gordon | Grant A | 8.7K | $0 |
| May 14, 2026 | Garen G Bohlin | Grant A | 8.7K | $0 |
| May 13, 2026 | Nancy Lurker | Sell S | 4.5K | $161.9K |
| May 11, 2026 | Garen G Bohlin | Exercise M | 8.7K | $0 |
| May 11, 2026 | Garen G Bohlin | Sell S | 8.7K | $323.5K |
| May 11, 2026 | Garen G Bohlin | Exercise M | 8.7K | $143.5K |
| Mar 18, 2026 | David Dieter 10b5-1 | Sell S | 14.0K | $488.1K |
| Mar 17, 2026 | David Dieter | Other F | 8.8K | $315.8K |
| Mar 9, 2026 | David Dieter 10b5-1 | Sell S | 6.2K | $228.1K |
| Mar 3, 2026 | Scott Dreyer 10b5-1 | Sell S | 3.6K | $145.9K |
| Mar 3, 2026 | Scott Dreyer 10b5-1 | Sell S | 46.4K | $1.9M |
| Feb 10, 2026 | David Dieter | Other F | 2.8K | $130.0K |
| Feb 10, 2026 | David Dieter | Grant A | 9.0K | $0 |
| Feb 10, 2026 | David Dieter | Grant A | 22.2K | $0 |
| Feb 10, 2026 | Colleen Tupper KEY | Other F | 26.7K | $1.2M |
| Feb 10, 2026 | Colleen Tupper KEY | Other F | 11.9K | $554.5K |
| Feb 10, 2026 | Colleen Tupper KEY | Grant A | 32.7K | $0 |
| Feb 10, 2026 | Colleen Tupper KEY | Grant A | 26.4K | $0 |
| Feb 10, 2026 | Thomas B Smith | Other F | 11.5K | $539.4K |
| Feb 10, 2026 | Thomas B Smith | Other F | 5.9K | $275.7K |
| Feb 10, 2026 | Thomas B Smith | Grant A | 22.8K | $0 |
| Feb 10, 2026 | Thomas B Smith | Grant A | 14.3K | $0 |
| Feb 10, 2026 | Scott Dreyer | Other F | 21.6K | $1.0M |
| Feb 10, 2026 | Scott Dreyer | Other F | 10.0K | $466.4K |
| Feb 10, 2026 | Scott Dreyer | Grant A | 30.7K | $0 |
| Feb 10, 2026 | Scott Dreyer | Grant A | 19.0K | $0 |
| Feb 10, 2026 | Vikram Karnani KEY | Other F | 11.3K | $528.1K |
| Feb 10, 2026 | Vikram Karnani KEY | Grant A | 32.5K | $0 |
| Feb 10, 2026 | Vikram Karnani KEY | Grant A | 79.3K | $0 |
About COLL insider trading
This page tracks insider transactions for COLLEGIUM PHARMACEUTICAL, INC (COLL) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.